LINC00472 affects pancreatic β-cell function in type 2 diabetes mellitus by targeting miR-320b.

OBJECTIVE

This study aimed to explore the role of LINC00472 in type 2 diabetes mellitus (T2DM).

METHODS

Serum LINC00472 expression was detected in 34 patients with T2DM and 45 healthy controls via RT-qPCR, with ROC curve analysing its diagnostic value. Mouse pancreatic β-cell line INS-1 was induced with high glucose (HG) to establish HG-INS-1 model. si-LINC00472 and miR-320b inhibitor were transfected into HG-INS-1. CCK-8, flow cytometry, and ELISA kits were used to detect cell viability, apoptosis, insulin level, and oxidative stress indicators. Subcellular fractionation, dual-luciferase reporter, and RIP assays verified the interaction between LINC00472 and miR-320b.

RESULTS

Serum LINC00472 was elevated in T2DM patients, with AUC = 0.882, 73.81% sensitivity, and 94.29% specificity. Silencing LINC00472 enhanced HG-INS-1 viability, reduced apoptosis, increased insulin, decreased ROS/MDA, and increased GSH. LINC00472 was mainly cytoplasmic and targeted miR-320b.

CONCLUSION

LINC00472 is a potential T2DM biomarker.